Analyst Ratings For Amgen, Inc. (NASDAQ:AMGN)
Today, Mizuho reiterated its Buy rating on Amgen, Inc. (NASDAQ:AMGN) with a price target of $208.00.
There are 10 Buy Ratings, 8 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Amgen, Inc. (NASDAQ:AMGN) is Buy with a consensus target price of $207.00 per share, a potential 11.47% upside.
Some recent analyst ratings include
- 6/24/2019-Amgen, Inc. (NASDAQ:AMGN) had its Buy rating reiterated by Mizuho with a $208.00 price target
- 5/22/2019-Amgen, Inc. (NASDAQ:AMGN) gets upgraded to Buy by Citigroup with a price target of $205.00
- 5/21/2019-Amgen, Inc. (NASDAQ:AMGN) had its Neutral rating reiterated by Royal Bank of Canada with a $192.00 price target
- 5/20/2019-Amgen, Inc. (NASDAQ:AMGN) has coverage initiated with a Outperform rating and $208.00 price target
- 5/15/2019-Amgen, Inc. (NASDAQ:AMGN) had its Hold rating reiterated by JPMorgan Chase & Co. with a $190.00 price target
- 5/1/2019-Amgen, Inc. (NASDAQ:AMGN) had its Buy rating reiterated by Cowen with a $229.00 price target
About Amgen, Inc. (NASDAQ:AMGN)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. Read More…
Recent Trading Activity for Amgen, Inc. (NASDAQ:AMGN)
Shares of Amgen, Inc. closed the previous trading session at 185.72 −1.39 0.74% with 186.07 shares trading hands.
